Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, United States.
J Immunol Methods. 2013 Apr 30;390(1-2):99-105. doi: 10.1016/j.jim.2013.02.001. Epub 2013 Feb 8.
Highly sensitive and reliable assays based on the quantitation of immunologically relevant component(s) in recombinant or whole parasite-based vaccines would facilitate pre-clinical and clinical phases and the monitoring of malaria vaccine deployment. Here we report a laboratory-grade Western Blot assay for quantitative detection of Plasmodium falciparum circumsporozoite protein (PfCSP) in P. falciparum sporozoite (PfSPZ) and in recombinant (rPfCSP) product. This assay is based on the immuno-reactivity of an anti-P. falciparum CSP monoclonal antibody (mAb 2A10) with the NANP-repeat units on PfCSP. The antigen-antibody complex is detected by reaction with a commercially obtained chemiluminescence-linked Immunodetection system. The linear range for detecting the recombinant P. falciparum CSP (rPfCSP) in this assay is 3-12pg (R(2)=0.9399). The range for detecting the day 15 salivary-gland PfSPZ is between 0.0625 and 1 parasite (R(2)=0.9448) and approximately 10.0pg of PfCSP was detected on each sporozoite. The assay was highly reproducible in measuring the PfCSP on PfSPZ. The inter-assay Coefficient of Variation (CV%) was 10.31% while the intra-assay CV% on three different days was 6.05%, 2.03% and 1.42% respectively. These results suggest that this ECL-WB assay is highly sensitive and robust with a low degree of inter-assay and intra-assay variations. To our knowledge, this is the most sensitive immunoassay for the detection of a recombinant or native malarial protein and may have a wider range of applications including the quantification of immunological component(s) in a vaccine formulation, determination of the antigenic integrity in adjuvanted-vaccine and in stability studies. In addition, this assay can be applied to measure the mosquito infectivity in malaria transmission areas and to determine the effects of intervention measures on malaria transmission.
基于对重组或全寄生虫疫苗中免疫相关成分的定量检测的高灵敏度和可靠的检测方法将有助于临床前和临床阶段以及疟疾疫苗部署的监测。在这里,我们报告了一种实验室级别的 Western Blot 检测方法,用于定量检测恶性疟原虫裂殖子(PfSPZ)和重组(rPfCSP)产品中的恶性疟原虫环子孢子蛋白(PfCSP)。该检测方法基于抗恶性疟原虫 CSP 单克隆抗体(mAb 2A10)与 PfCSP 上的 NANP 重复单元的免疫反应性。抗原-抗体复合物通过与商业获得的化学发光免疫检测系统反应来检测。该检测方法检测重组恶性疟原虫 CSP(rPfCSP)的线性范围为 3-12pg(R(2)=0.9399)。检测第 15 天唾液腺 PfSPZ 的范围在 0.0625 至 1 个寄生虫(R(2)=0.9448)之间,每个裂殖子上大约检测到 10.0pg 的 PfCSP。该检测方法在测量 PfSPZ 上的 PfCSP 时具有高度的重现性。批内变异系数(CV%)为 10.31%,而在三天的批内 CV%分别为 6.05%、2.03%和 1.42%。这些结果表明,该 ECL-WB 检测方法具有高度的灵敏度和稳健性,批内和批间变异程度较低。据我们所知,这是检测重组或天然疟原虫蛋白的最敏感免疫检测方法,可能具有更广泛的应用范围,包括疫苗制剂中免疫成分的定量、佐剂疫苗中抗原的完整性以及稳定性研究。此外,该检测方法可用于测量疟疾传播地区的蚊子感染性,并确定干预措施对疟疾传播的影响。